Capricor Therapeutics News

Capricor Therapeutics Updates on Duchenne Treatment Progress

TipRanksApr 29 21:42

Buy Rating Affirmed for Capricor Therapeutics Amidst Positive FDA Discussions and Clinical Advancements

TipRanksApr 27 19:35

HC Wainwright & Co. : The Capricorn Therapeutics (CAPR.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $40.00.

HC Wainwright & Co. : The Capricorn Therapeutics (CAPR.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $40.00.

Zhitong FinanceApr 25 19:30

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics with a Buy and maintains $40 price target.

Analyst UpgradesApr 25 19:25

Capricor Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 663.36% HC Wainwright & Co. → $40 Reiterates Buy → Buy 03/01/2024 663.36% HC Wainwright & Co. →

BenzingaApr 25 19:24

Optimistic Outlook for Capricor Therapeutics: Buy Rating Affirmed Amid Regulatory Progress and Strong Financial Position

TipRanksApr 25 18:25

Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug

Capricor Therapeutics (CAPR) said Wednesday the US Food and Drug Administration granted another Type-B meeting in Q2 to move ahead with the biologics license application for CAP-1002 for treating Duch

MT NewswiresApr 25 03:21

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Yahoo FinanceApr 25 00:42

Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals Among Healthcare Movers

Seeking AlphaApr 24 22:00

Capricor Therapeutics Announces Type-B Meeting With FDA For CAP-1002 Program For Duchenne Muscular Dystrophy, FDA Feedback Supports Requests For Pre-BLA Meeting And Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting

Capricor Therapeutics Announces Type-B Meeting With FDA For CAP-1002 Program For Duchenne Muscular Dystrophy, FDA Feedback Supports Requests For Pre-BLA Meeting And Subsequent Rolling BLA Submission F

BenzingaApr 24 21:04

Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug

Seeking AlphaApr 23 22:29

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Stock Catapults 51% Though Its Price And Business Still Lag The Industry

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares have had a really impressive month, gaining 51% after a shaky period beforehand. Looking back a bit further, it's encouraging to see the stock is up

Simply Wall StApr 3 18:55

Solid Biosciences Gets FDA Rare Pediatric Disease Status for DMD Therapy

Seeking AlphaApr 1 22:17

Canopy Growth, Capricor Therapeutics, GT Biopharma Among Healthcare Movers

Seeking AlphaMar 22 22:00

This Just In: Analysts Are Boosting Their Capricor Therapeutics, Inc. (NASDAQ:CAPR) Outlook for This Year

Shareholders in Capricor Therapeutics, Inc. (NASDAQ:CAPR) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The analysts greatly increased

Simply Wall StMar 16 20:59

Catalyst Announces US Launch of Duchenne MD Drug Agamree

Seeking AlphaMar 14 01:46

Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?

Yahoo FinanceMar 13 21:40

Capricor Therapeutics, Inc. Is Worried About This – Should You Be Worried Too?

TipRanksMar 12 14:01

Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare

GlobeNewswireMar 6 21:30

Capricor Therapeutics: Strong Buy Rating Backed by Robust Financials and Promising Clinical Progress

TipRanksMar 6 01:55